Elanco Animal Health Incorporated reported a strong finish to 2024, achieving its sixth consecutive quarter of organic constant currency revenue growth, with the fourth quarter up 4%. For the full year 2024, total revenue was $4,439 million, flat on a reported basis but up 3% in organic constant currency, driven by growth in both Pet Health and Farm Animal segments.
Fourth quarter adjusted EPS increased by 75% year-over-year to $0.14, and adjusted EBITDA rose 7% to $177 million. For the full year, adjusted EPS was $0.91, up 2%, while adjusted EBITDA was $910 million, down 7% compared to 2023. The company generated over half a billion dollars of operating cash flow in 2024, doubling from the prior year.
For the full year 2025, Elanco provided initial guidance with revenue expected between $4,445 million and $4,510 million, adjusted EBITDA between $830 million and $870 million, and adjusted EPS between $0.80 and $0.86. The company anticipates accelerating mid-single-digit organic constant currency revenue growth, but expects operating expenses to increase approximately 6% due to strategic investments in global innovation launches and foreign exchange headwinds.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.